肿瘤细胞治疗研究
英文原题：Genetic lesions and targeted therapy in Hodgkin lymphoma.
Genetic lesions and targeted therapy in Hodgkin lymphoma.
霍奇金淋巴瘤是一种特殊类型的淋巴瘤，其肿瘤细胞常发生多种基因病变，并伴有相应的通路异常。
霍奇金淋巴瘤是一种特殊类型的淋巴瘤，其肿瘤细胞常发生多种基因病变，并伴随相关信号通路异常。异常通路主要包括活化的JAK-STAT（Janus激酶-信号转导及转录激活因子）通路和NF-κB（核因子κB）通路，通常会导致存活信号过度活跃。靶向治疗在血液系统恶性肿瘤中常发挥重要作用，例如在弥漫性大B细胞淋巴瘤中使用靶向CD19和CD22的CAR-T疗法；而霍奇金淋巴瘤的主要靶向治疗靶点为CD30和PD-1，也有其他分子靶向药物正在研究。本文综述可靶向的基因病变、霍奇金淋巴瘤现有治疗选择和临床试验，并探讨这些基因病变在临床应用中的潜在价值。
Hodgkin lymphoma is a special type of lymphoma in which tumor cells frequently undergo multiple genetic lesions that are associated with accompanying pathway abnormalities. These pathway abnormalities are dominated by active signaling pathways, such as the JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway and the NF B (nuclear factor kappa-B) pathway, which usually result in hyperactive survival signaling. Targeted therapies often play an important role in hematologic malignancies, such as CAR-T therapy (chimeric antigen receptor T-cell immunotherapy) targeting CD19 and CD22 in diffuse large B-cell lymphoma, while in Hodgkin lymphoma, the main targets of targeted therapies are CD30 molecules and PD1 molecules. Drugs targeting other molecules are also under investigation. This review summarizes the actionable genetic lesions, current treatment options, clinical trials for Hodgkin lymphoma and the potential value of those genetic lesions in clinical applications.
MEMBER ACCOUNT
登录成功会直接打开下一页。
